This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reeves, J. R. Articles by Ramnani, D. M. Search for Related Content PubMed PubMed Citation Articles by Reeves, J. R. Articles by Ramnani, D. M.

Prognostic Value of Prostate Secretory Protein of 94 Amino Acids and its Binding Protein after Radical Prostatectomy

Authors' Affiliations: ¹ Ambrilia Biopharma Inc., Chemin du Golf, Verdun, Quebec, Canada and ² Virginia Urology, Richmond, Virginia

Requests for reprints: Jonathan R. Reeves, Ambrilia Biopharma, Inc., 1000 Chemin du Golf, Verdun, Quebec, Canada H3E 1H4. Phone: 514-751-2003; E-mail: jonathan.reeves{at}sympatico.ca.

Purpose: To establish the prognostic value of total and free prostate secretory protein of 94 amino acids (PSP94) and the PSP94-binding protein (PSPBP) following radical prostatectomy.

Experimental Design: One hundred and eighty-five serum samples were obtained from patients with localized prostate cancer prior to treatment with radical prostatectomy at Virginia Urology (Richmond, VA). Patients were followed up for a median of 48 months (range, 1-66 months) and biochemical relapse was indicated as total prostate-specific antigen (tPSA) levels increasing to >0.1 ng/mL. The available clinical variables included initial tPSA, Gleason score, surgical margin status, and clinical stage. Total PSP94, free PSP94, and the PSPBP were quantified in the pretreatment serum using new ELISA tests (Medicorp, Inc. and Ambrilia Biopharma, Inc., Montreal, Quebec, Canada). Univariate and multivariate Cox proportional hazards models were used to assess the ability of PSP94 and PSPBP to predict time to recurrence.

Results: Thirty-one patients had biochemical recurrence. Gleason score, margin status, clinical stage, and initial tPSA significantly predicted recurrence risk (all P < 0.001). In addition, PSPBP was negatively associated with recurrence risk (P = 0.005), and, consistent with previous studies, the bound/free PSP94 ratio was positively associated with recurrence risk (P = 0.008). Multivariate analysis showed that PSPBP, as well as the bound/free PSP94 ratio, were independent predictors of biochemical relapse risk adjusting for tPSA, Gleason score, and margin status.

Conclusions: Bound/free PSP94 and PSPBP are novel and independent prognostic markers following radical prostatectomy for prostate cancer.

This article has been cited by other articles:

				H. Lou, M. Yeager, H. Li, J. G. Bosquet, R. B. Hayes, N. Orr, K. Yu, A. Hutchinson, K. B. Jacobs, P. Kraft, et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility PNAS, May 12, 2009; 106(19): 7933 - 7938. [Abstract] [Full Text] [PDF]

				G. M. Gibbs, K. Roelants, and M. K. O'Bryan The CAP Superfamily: Cysteine-Rich Secretory Proteins, Antigen 5, and Pathogenesis-Related 1 Proteins--Roles in Reproduction, Cancer, and Immune Defense Endocr. Rev., December 1, 2008; 29(7): 865 - 897. [Abstract] [Full Text] [PDF]

				Z. Kote-Jarai, D. F. Easton, J. L. Stanford, E. A. Ostrander, J. Schleutker, S. A. Ingles, D. Schaid, S. Thibodeau, T. Dork, D. Neal, et al. Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2052 - 2061. [Abstract] [Full Text] [PDF]

				A. S. Bjartell, H. Al-Ahmadie, A. M. Serio, J. A. Eastham, S. E. Eggener, S. W. Fine, L. Udby, W. L. Gerald, A. J. Vickers, H. Lilja, et al. Association of Cysteine-Rich Secretory Protein 3 and {beta}-Microseminoprotein with Outcome after Radical Prostatectomy Clin. Cancer Res., July 15, 2007; 13(14): 4130 - 4138. [Abstract] [Full Text] [PDF]